Neurologists increasingly favour low dose levodopa over dopamine agonists to avoid severe behavioral side effects in early stage Parkinson's

Dopamine agonists are losing ground to levodopa as the preferred first line treatment for Parkinson's due to growing concerns over impulse control disorders and neuropsychiatric side effects. Medical practice is experiencing a distinct shift in how early stage Parkinson's is managed. For years, dopamine agonists like pramipexole, ropinirole, and rotigotine patch were routinely prescribed as the initial therapy, particularly for younger people. The long standing strategy was to delay the introduction of levodopa for as long as possible to postpone the onset of involuntary movements known as dyskinesia. However, recent insights from major neurological conferences, including the French Congress of Neurology (JNLF), indicate that the clinical tide has turned. Specialists are increasingly moving away from dopamine agonists in favour of starting directly with low dose levodopa, which remains the most effective tool for managing movement symptoms. The primary driver behind this clinical shift is a deeper understanding of the psychiatric and behavioral complications tied to dopamine agonists. While these medications mimic dopamine in the brain to improve movement, they heavily stimulate specific dopamine pathways linked to reward and motivation. This stimulation can trigger severe impulse control disorders, leading to compulsive behaviors such as hypersexuality, pathological gambling, binge eating, and reckless spending. Recent clinical evidence highlights that these complex side effects occur more frequently than previously recognized, causing profound disruption to personal relationships and finances before being identified. Because these behavioral shifts can be insidious and difficult for people or their families to recognise initially, clinicians are adopting a much more conservative approach to prescribing them. In addition to impulse control challenges, dopamine agonists carry a higher risk of other burdensome side effects compared to levodopa, especially in older adults. These include significant daytime sleepiness, sudden sleep attacks, hallucination, confusion, and fluid retention causing leg swelling. Conversely, long term data has shown that the fear of levodopa induced dyskinesia was perhaps overstated in the past, particularly when levodopa is managed carefully at the lowest effective dose. By prioritizing low dose levodopa early on, clinicians can achieve excellent symptom control with a significantly cleaner psychological safety profile, transforming the standard of care for those newly diagnosed with Parkinson's.